<DOC>
	<DOCNO>NCT00896909</DOCNO>
	<brief_summary>RATIONALE : Collecting sample tumor tissue patient cancer study laboratory may help doctor learn change may occur DNA identify biomarkers related cancer . PURPOSE : This laboratory study look HER-2 mutation tumor sample patient advance non-small cell lung cancer treat trastuzumab clinical trial ECOG-2598 .</brief_summary>
	<brief_title>HER-2 Mutations Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated Clinical Trial ECOG-2598</brief_title>
	<detailed_description>OBJECTIVES : - Correlate clinical response trastuzumab ( Herceptin® ) presence mutation HER-2 kinase domain tumor sample patient advance non-small cell lung cancer treat protocol ECOG-2598 . - Correlate mutation time progression survival patient . OUTLINE : This multicenter study . Tissue specimens analyzed polymerase chain reaction assess mutation HER-2 gene . Laboratory/biomarker analysis data correlate clinical data protocol ECOG-2598 . PROJECTED ACCRUAL : A total 22-44 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis nonsmall cell lung cancer meeting ≥ 1 follow criterion : Recurrent disease Stage IIIB pleural pericardial effusion Stage IV disease Treated protocol ECOG2598 PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>